Infliximab Concentrations in Participants with Moderate to Severe COVID-19

the ACTIV-1 Study Team

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)490-491
Number of pages2
JournalJournal of Clinical Pharmacology
Volume64
Issue number4
DOIs
StatePublished - Apr 2024

Keywords

  • COVID-19
  • infliximab
  • pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this